Please login to the form below

Not currently logged in
Email:
Password:

UK pharma HCP payment database goes live

Two-thirds of payments related to research and development work
ABPI

UK pharma has published details of the payments and benefits in kind it provides to doctors, nurses and pharmacists as long-awaited industry transparency rules come into force.

The ABPI's publically-available database, Disclosure UK, reveals the industry paid healthcare professionals (HCPs) £340.3m in 2015, two-thirds of which (£229.3m) was for R&D work.

The remaining £111m was for a range of commercial rather than R&D activities, with nearly half of that money (£49.3m) going on a range of service and consultancy fees.

The next largest chunk of money was for event-related payments, which accounted for £31.4m in 2015, with £10.8m of that going on travel and accommodation.

Closely behind that were donations and grants to healthcare organisations, on which UK pharma companies spent £30.3m in 2015.

Mike Thompson, chief executive for the ABPI, said: “This is a milestone moment for transparency in our industry and for the vital partnerships we have with health professionals and organisations across the UK.

“These partnerships matter and help our industry bring the right medicine to the right patient at the right time so we can improve quality of life and, in many cases, save lives.”

He added that the work NHS doctors, nurses and health professionals for pharma is often undertaken in addition to their day job and that “it's right we pay for that expertise and insight”.

However, companies have faced some difficulties persuading the HCPs they work with to disclose their own details, and 30% of those featured in the new database refused to be named.

The Disclosure UK database shows payments from 109 pharmaceutical companies in the UK (54 of which are ABPI members).

It allows individual recipients of payments to be searched by name (where permission has been given), healthcare profession or organisation and their professional address.

The requirement for UK companies to publish this data was earlier this year enshrined in the ABPI's Code of Practice and is also part of a Europe-wide transparency initiative.

That work, led by EFPIA and following on from similar efforts in the US, has seen 33 countries in Europe make public their pharma payments and benefits in kind this year.

Article by
Dominic Tyer

1st July 2016

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Tapping the potential of rare diseases: A journey into uncharted territory
...
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...

Infographics